A retrospective analysis of medications associated with pityriasis rosea reported in the FDA adverse events reporting system

被引：0
|
作者：
Mashoudy, Kayla D. [1 ]
Ye-Tay, Joselyn [2 ]
Nouri, Keyvan [1 ]
机构：
[1] Univ Miami, Miller Sch Med, Dr Phillip Frost Dept Dermatol & Cutaneous Surg, 1150 NW 14th St, Miami, FL 33136 USA
[2] Nicklaus Childrens Hosp, Dept Pediat, 3100 SW 62nd Ave, Miami, FL 33155 USA
来源：
ARCHIVES OF DERMATOLOGICAL RESEARCH | 2025年 / 317卷 / 01期
关键词：
Pityriasis rosea; Drug-induced; FDA adverse events; TNF inhibitors; ACE inhibitors; Biologics; Pharmacovigilance; Adverse drug reactions; Dermatology; Epidemiology; DENDRITIC CELLS; PSORIASIS; ERUPTION; THERAPY; GIBERT; SERUM;
D O I：
10.1007/s00403-024-03763-x
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
Pityriasis rosea (PR) is an acute exanthematous disease with an uncertain physiopathology, increasingly recognized as potentially drug induced. This study aims to investigate medication triggers associated with PR by analyzing cases reported in the FDA Adverse Event Reporting System (FAERS) database. A retrospective review of 343 PR cases reported in the FAERS database from January 1, 1998, to March 31, 2024, was conducted. Reporting odds ratios (ROR) were calculated to assess associations between PR and specific drug classes, including tumor necrosis factor (TNF) inhibitors and angiotensin-converting enzyme (ACE) inhibitors. Logistic regression analysis evaluated the influence of factors such as sex, age group, and seriousness of outcomes on the occurrence of PR. Females represented 56.3% of cases and the 18-64 age group comprised 55.4% of cases. TNF inhibitors were significantly associated with PR (ROR = 4.1881 [3.1970-5.4865], P < 0.0001), particularly infliximab (ROR = 6.5284 [3.9523-10.7837], P < 0.0001), etanercept (ROR = 3.4921 [2.2873-5.3315], P < 0.0001), and adalimumab (ROR = 3.086 [2.0213-4.7115], P < 0.0001). ACE inhibitors were also associated with PR (ROR = 9.9808 [6.0423-16.4864], P < 0.0001), with higher odds in older patients (OR 14.08 [4.2-47.2], P < 0.0001) and those reporting serious outcomes (OR 9.53 [1.24-72.99], P = 0.03). Based on the FAERS, there has been a consistent rise in PR cases, with TNF inhibitors and ACE inhibitors being associated medication classes tied to PR. Given the limited literature on drug-related triggers and patient demographics, we aimed to highlight the characteristics of PR cases that could enhance awareness and inform better clinical outcomes for affected patients.
引用
收藏
页数：8
相关论文
共 50 条
  • [21] CARDIOVASCULAR EVENTS ASSOCIATED WITH COMBINATION MEK/BRAF INHIBITORS (ANALYSIS OF THE FDA ADVERSE EVENTS REPORTING SYSTEM)
    Guha, Avirup
    Fradley, Michael
    Lenihan, Daniel
    Jain, Prantesh
    Oliveira, Guilherme
    Al-Kindi, Sadeer
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2020, 75 (11) : 728 - 728
  • [22] CARDIOVASCULAR EVENTS ASSOCIATED WITH CAR-T THERAPY (ANALYSIS OF THE FDA ADVERSE EVENTS REPORTING SYSTEM)
    Guha, Avirup
    Addison, Daniel
    Ghosh, Arjun
    Roddie, Claire
    de Lima, Marcos
    Al-Kindi, Sadeer
    Oliveira, Guilherme
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2020, 75 (11) : 332 - 332
  • [23] Adverse Events of Desvenlafaxine Using FDA Adverse Events Reporting System
    Karydes, H. C.
    Leikin, J. B.
    CLINICAL TOXICOLOGY, 2010, 48 (06) : 664 - 664
  • [24] COMMONLY REPORTED ADVERSE EVENTS ASSOCIATED WITH ANTICOAGULANTS USING FDA ADVERSE EVENT REPORTING SYSTEM DATABASE 2012-2018
    Costa, L.
    Hincapie, A.
    Guo, J. J.
    VALUE IN HEALTH, 2019, 22 : S163 - S163
  • [25] Assessing Adverse Drug Reactions Reported for New Respiratory Medications in the FDA Adverse Event Reporting System Database
    Kim, Hyunwoo
    Pfeiffer, Colin M.
    Gray, Matthew P.
    Stottlemyer, Britney A.
    Boyce, Richard D.
    Kane-Gill, Sandra L.
    RESPIRATORY CARE, 2021, 66 (11) : 1739 - 1745
  • [26] Psoriasis adverse events and associated medications as reported in the US Food and Drug Reporting System from 2016 to 2021
    Learned, Christine
    Alsukait, Sara
    Deverapalli, Sandhya
    Elliott, Erika
    Moody, Katherine
    Sobell, Jeffrey
    Konnikov, Nellie
    Ortega, Melissa
    Rosmarin, David
    JAAD INTERNATIONAL, 2022, 7 : 144 - 145
  • [27] Adverse Events Reported with Therapies Targeting the CGRP Pathway During the First 6 Months Post-launch: A Retrospective Analysis Using the FDA Adverse Events Reporting System
    Stephen D. Silberstein
    Shoshana Reshef
    Joshua M. Cohen
    Sanjay Gandhi
    Michael Seminerio
    Verena Ramirez Campos
    Yoel Kessler
    Stephen F. Thompson
    Andrew Blumenfeld
    Advances in Therapy, 2023, 40 : 445 - 459
  • [28] Adverse Events Reported with Therapies Targeting the CGRP Pathway During the First 6 Months Post-launch: A Retrospective Analysis Using the FDA Adverse Events Reporting System
    Silberstein, Stephen D.
    Reshef, Shoshana
    Cohen, Joshua M.
    Gandhi, Sanjay
    Seminerio, Michael
    Campos, Verena Ramirez
    Kessler, Yoel
    Thompson, Stephen F.
    Blumenfeld, Andrew
    ADVANCES IN THERAPY, 2023, 40 (02) : 445 - 459
  • [29] Adverse events of celecoxib associated with the central nervous system and cancer: a disproportionality analysis of the FDA adverse event reporting system
    Du, Yikuan
    Zhang, Mengting
    Chen, Mianhai
    Hu, Mianda
    Zeng, Wenqi
    Cai, Xiaolin
    Zhang, Weichui
    Zhu, Jinfeng
    Zhong, Mingjun
    Liu, Yi
    Yang, Chun
    EXPERT OPINION ON DRUG SAFETY, 2025,
  • [30] Serious Cardiovascular Adverse Events Reported with Intravenous Sedatives: A Retrospective Analysis of the MedWatch Adverse Event Reporting System
    Duprey, Matthew S.
    Al-Qadheeb, Nada S.
    O'Donnell, Nick
    Hoffman, Keith B.
    Weinstock, Jonathan
    Madias, Christopher
    Dimbil, Mo
    Devlin, John W.
    DRUGS-REAL WORLD OUTCOMES, 2019, 6 (03) : 141 - 149
12345